WebMar 8, 2024 · Voyager will receive $54 million upfront and is entitled to receive up to $37.5 million in exercise fees for options for three initial CNS targets, exercisable by Novartis within 12 months of signing. WebNov 22, 2024 · Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. ... Novartis Media Relations E-mail: [email protected] Central North America Richard Jarvis +41 79 ...
Did you know?
WebMar 7, 2024 · Voyager Therapeutics, Inc. March 7, 2024, 4:00 AM · 14 min read. Voyager Therapeutics, Inc. - Transformational progress in 2024 marked by reprioritization of high-value neurology pipeline and ... WebMar 7, 2024 · CAMBRIDGE, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. ( Nasdaq: VYGR ), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported fourth quarter and full year 2024 financial and operating results.
WebMar 8, 2024 · CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing … WebMar 27, 2024 · Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a ...
WebMar 8, 2024 · CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today reported fourth quarter and full year 2024 financial and operating results. WebOct 6, 2024 · CAMBRIDGE, Mass., Oct. 06, 2024(GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.(Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced an agreement through which Pfizer Inc(NYSE: PFE) may exercise options to …
WebMar 27, 2024 · Novartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs Novartis and …
WebMar 8, 2024 · Language & Country Selector for Desktop. Global en . Choose Location incoterms legiscomexWebNovartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for … incline bench row dumbellWebMar 7, 2024 · On March 7, 2024, Voyager Therapeutics, Inc. (the "Company") announced fourth quarter 2024 financial results and corporate updates. The full text of the press release issued in connection... incline bench shrugWebMar 8, 2024 · License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two ... incoterms latestWebMar 6, 2024 · CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking … incline bent over rowWebCAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next … incline bench reverse flysWebMar 6, 2024 · CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking … incline block tariff